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Antonio Colombo, MD,y Neil Ruparelia, MB BS, DPHILyzT wenty years ago, Drs. Patrick Serruys andCarlo Di Mario wrote an editorial in Circula-tion titled “Who Was Thrombogenic: The
Stent or the Doctor?” (1), that discussed optimal stent
implantation technique. They highlighted the critical
roles played by both the use of intravascular ultra-
sound to optimize stent implantation and the admin-
istration of dual antiplatelet therapy (DAPT) to
prevent metal stent thrombosis (ST) (2). These sug-
gestions and considerations were particularly perti-
nent at the time, and although the designs of
metallic stents have evolved to make the technology
more forgiving, these factors are still valid and must
be seriously revisited when considering the use of
current early-generation bioresorbable scaffolds.SEE PAGE 12In this issue of JACC: Cardiovascular Interventions,
Lipinski et al. (3) present a systematic review and
meta-analysis evaluating the risk of ST following
implantation of the Absorb bioresorbable vascular
scaffold (BVS) (Abbott Vascular, Santa Clara, Califor-
nia) when compared with implantation of second-
generation drug-eluting stents (DES). The authors
performed a study-level meta-analysis of 25 studies
from 26 publications that included 10,510 patients
with a mean follow-up of 6.4  5.1 months. Absorb
BVS was implanted in 8,351 patients with an average
of 1.22  0.16 treated lesion/patient, whereas*Editorials published in JACC: Cardiovascular Interventions reﬂect the
views of the authors and do not necessarily represent the views of JACC:
Cardiovascular Interventions or the American College of Cardiology.
From the yDepartment of Interventional Cardiology, San Raffaele Scien-
tiﬁc Institute, and EMO-GVM, Centro Cuore Columbus, Milan, Italy; and
the zDepartment of Cardiology, Imperial College, London, United
Kingdom. Both authors have reported that they have no relationships
relevant to the contents of this paper to disclose.2,159 patients received metallic DES. In this study
population, 59% of patients underwent percutaneous
coronary intervention for acute coronary syndromes
(ACS), including BVS use in more complex lesions,
with only 16% of lesions being American Heart
Association/American College of Cardiology class A,
37% of lesions in class B1, 28% in class B2, and 19% in
class C.
Amongst 8,183 patients receiving a BVS, death
occurred in 0.8% of patients, cardiovascular death in
0.6% of patients, major adverse cardiovascular
events in 4.1% of patients, myocardial infarction in
2.1% of patients, target vessel revascularization in
2.7% of patients, target lesion revascularization
in 2.0% of patients, and deﬁnite or probable ST in
1.2% of the overall study population. There were 9
studies evaluating outcomes of BVS versus DES
comparing 1,948 patients who received a BVS with
2,150 patients who received a DES. No differences
were found between groups with regard to cardio-
vascular death, major adverse cardiovascular events,
target lesion revascularization, or target vessel
revascularization. It is not very clear from this study
what the actual incidence of ST in patients treated
with DES was, but the reported 1.2% overall incidence
of ST in BVS treated patients is far from being a
bad result! However, a detailed statistical analysis
showed that deﬁnite or probable ST was signiﬁcantly
increased following placement of a BVS compared
with a DES (odds ratio [OR]: 2.06 [95% conﬁdence
interval (CI): 1.07 to 3.98], I2 ¼ 0%; p ¼ 0.03), with
a trend toward an increase in deﬁnite scaffold
thrombosis (OR: 1.91 [95% CI: 0.82 to 4.46]; p ¼ 0.13)
and ST at 1 month (OR: 2.02 [95% CI: 0.69 to 5.93];
p ¼ 0.20).
These ﬁndings did not translate into an increase in
cardiovascular or all-cause mortality; thus, although
reassuring, the study should not temper our efforts to
lower the rates of ST. This objective can be achieved
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26because the doctor is in control of many of the aspects
that predispose to ST (4).
The number 1 procedural characteristic that
stands out from this study is the fact that post-
dilation was performed in only 52% of lesions. Aware
of the high compliance of the balloon on which the
Absorb BVS is mounted, we are surprised that post-
dilation was not performed in a greater number of
lesions. The potential sequelae of this procedural
omission is further multiplied in the absence of
intravascular imaging guidance, with low reported
usage rates in the larger published registries that
were included in this meta-analysis (5,6). To achieve
homogenous scaffold expansion and apposition, in
the absence of routine intravascular ultrasound or
optical coherence tomography evaluation, high-
pressure noncompliant balloon post-dilation needs
to be almost universally performed. The fact that
there was no correlation between post-dilation and
ST does not negate a role of post-dilation for the
following reasons:
1. This was a study-level analysis, and lesion-
speciﬁc details have not been analyzed (e.g.,
balloon/artery ratio, noncompliant balloon use,
maximal pressure of balloon inﬂation); therefore,
the general observations may be difﬁcult to
interpret.
2. By chance, post-dilation may have been per-
formed in lesions that did not need post-dilation
and not performed in lesions that needed post-
dilation.
3. Considering that ST occurred more frequently in
ACS (which represented the majority of the study
population), we need speciﬁc patient-level data
regarding post-dilation in this subset.
Along these lines, we are not surprised that
second-generation DES performed well in compari-
son with BVS. Current DES are manufactured with
thin struts in combination with drug-delivery sys-
tems promoting rapid endothelialization, and there-
fore, they are more forgiving toward procedural
optimization. The fact that the authors reported a
higher ST rate for Absorb BVS when compared with
DES in patients with ACS highlights the need for
speciﬁc improvement in this subset of patients. The
speciﬁc features of current Absorb BVS with stent
struts that are 157 um thicker and also wider when
compared to DES (2.5- and 3.0-mm BVS: 190.5 mm;
3.5-mm BVS: 215.9 mm) results in greater protrusion
(both length and height) of struts causing loss
of laminar ﬂow, with areas of oscillatory shear
stress promoting platelet activation (7). A report (8)
failing to demonstrate a relationship between strutthickness and ST does not negate the opposite ﬁnd-
ings collected over the past decades from both
experimental (7) and clinical studies (9,10). These
physical attributes demand the scaffold to be fully
post-dilated, embedding the struts deeply in the wall
of the vessel to avoid any malapposition and favoring
rapid endothelization. Additionally, it is of the
utmost importance that the largest possible lumen
cross-sectional area is achieved. Many studies (with
both metal stents and scaffolds) identify a small ﬁnal
lumen cross-sectional area as a predictor of ST (11).
DAPT following stent implantation is mandatory
to reduce the risk of ST (12). The fact that ST
occurred in 4 patients treated with BVS who stopped
DAPT prematurely is not a surprise and is not a
hallmark of increased dependency of these novel
devices upon DAPT. Indeed, no metal stent has been
immune to ST when DAPT has been stopped pre-
maturely (11).
The recent Absorb Japan study (13) reported a
similar 1.5% thrombosis rate with both Absorb and
everolimus-eluting stents (EES). A small residual in-
segment diameter was present in the 6 cases of ST
(4 BVS and 2 EES). This ST rate was conﬁrmed by the
TROFI II (Comparison of the Absorb Everolimus
Eluting Bioresorbable Vascular Scaffold System With
a Drug-Eluting Metal Stent [Xience] in Acute
ST-Elevation Myocardial Infarction) trial (14) that re-
ported 1 ST event (1.1%) in the BVS group compared
with 0 cases in the EES group. An important addi-
tional ﬁnding from the TROFI II study was that
lesions treated with BVS demonstrated nearly com-
plete arterial healing, comparable to that of EES at
6 months.
This debate highlights how the Virchow triad
for thrombogenesis can be almost completely
controlled by the operator. The doctor can optimize:
1) the lumen with appropriate pre- and post-dilation
(with judicious use of rotational atherectomy or
scoring balloons as required); and 2) the ﬂow by
selecting the appropriate vessel (with adequate
run-off, supplying viable myocardium) to be stented.
However, the third element of the triad—the optimal
modulation of blood thrombogenicity with anti-
platelet therapy—remains uncertain. Despite the
recent ﬁndings of the ADAPT-DES (Platelet Reac-
tivity and Clinical Outcomes After Coronary Artery
Implantation of Drug-Eluting Stents) study (15)
showing a relationship between ST and the degree
of platelet inhibition, it is still unclear how best to
individualize (regimen and duration) antiplatelet
therapy.
The important ﬁnal message we should take away
from this study is: “Absorb BVS may have a higher
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27risk of ST, but this can be overcome by the operator
who is in charge to ensure optimal implantation”.
Looking forward, there is no darkness or uncertainty
in the tunnel of ST. We are in control and we can shed
the light!REPRINT REQUESTS AND CORRESPONDENCE: Dr.
Antonio Colombo, EMO-GV Centro Cuore Columbus,
Via Buonarroti 48, 20145 Milan, Italy. E-mail: info@
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